Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

NeoGenomics Inc. ($NEO) reported inking a new deal with Thermo Fisher Scientific. The deal allows the company to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. NeoGenomics offers the newly FDA-approved Oncomine Dx Target Test for Non-Small Cell Lung Cancer (NSCLC). It is one of the first laboratories to offer this test. The methodology allows rapid analysis of samples compared to previously approved testing approaches. The company’s Pharma Services Division supported the analytical validation of the Oncomine Dx Target Test for submission to the FDA. The test evaluates 23 genes associated with NSCLC.
The stock reacted positively to the news and gained in its previous trading session.

Novo Nordisk ($NVO) received a boost as the new data from a real-world study, EU-TREAT, showed the benefits of its once-daily Tresiba to type 1 and type 2 diabetics. The data showed that Type 2 diabetics with well-controlled HbA1c with basal insulin experienced a 67% reduction in the rate of hypoglycemic events over a six-month period after switching to Tresiba with an 11% lower dose of insulin. Type 1 diabetics with controlled blood sugar levels experienced a 16% reduction in the rate of hypoglycemia over a six-month period after switching to Tresiba with a 13% lower insulin dose.


Nabriva Therapeutics ($NBRV) announced completing the enrollment of 738 subjects in a second Phase 3 study, LEAP 2, assessing lefamulin compared to oral moxifloxacin in adult patients with moderate community-acquired bacterial pneumonia (CABP). The company expects the topline results to available in the second quarter of next year.

CVS Health ($CVS) announced its financing strategy for the takeover of Aetna. The company plans to fund $69 billion deal with $44.8 billion in new debt, $21 billion in new equity and $4.1 billion of cash on hand.

Merck ($MKGAF) announced receiving the approval of Health Canada for its MAVENCLAD (Cladabrine Tablets) as monotherapy to treat adult patients with relapsing-remitting multiple sclerosis. The drug was approved in Europe in August.

Eli Lilly ($LLY) reported the FDA approval for its Taltz (ixekizumab) for the treatment of adults with active psoriatic arthritis. The drug was first approved in the U.S. in March 2016 for severe plaque psoriasis.


Collegium Pharmaceuticals ($COLL) announced inking a new deal with Depomed. The agreement grants Collegium the rights to commercialize pain med Nucynta (tapentadol) Immediate Release and Nucynta ER Extended Release tablets in the U.S.
Fortress Biotech ($FBIO) reported inking a licensing agreement with Harvard's Office of Technology Development securing rights to technologies for off-the-shelf CAR-T therapies and CRISPR/Cas9 gene editing platforms. The company has also signed a research collaboration agreement with Boston's Beth Israel Deaconess Medical Center aimed at developing CRISPR/Cas9-enhanced CAR-Ts.

Brokerage Company Name Rating Price
Target Impact on
Share Price Actions
Royal Bank Of Canada
Biogen (BIIB)
Sector Perform $321.00 N/A
BMO Capital Markets
Audentes Therapeutics (BOLD)
Outperform Low

Seaport Global Securities
BeyondSpring (BYSI)
Buy N/A
Needham & Company LLC
Collegium Pharmaceutical (COLL)
Buy $25.00 -> $28.00 Low

Jefferies Group
Collegium Pharmaceutical (COLL)
Buy $27.00 Low

Depomed (DEPO)
Neutral -> Buy $9.00 Low